Boston Scientific reports positive HI-PEITHO and CHAMPION-AF trial results

BOSTON SCIENTIFIC CORP

HI-PEITHO: EKOS plus anticoagulation reduced primary endpoint events by 61% vs anticoagulation alone (4.0% vs 10.3%, P=0.005).
HI-PEITHO: No episodes of intracranial bleeding through 30 days; results published in NEJM.
CHAMPION-AF: WATCHMAN FLX showed 45% relative reduction in non-procedural major bleeding vs NOACs (10.9% vs 19.0%, P<0.001).
CHAMPION-AF: Primary efficacy endpoint met with non-inferiority to NOACs for stroke, CV death, or systemic embolism (5.7% vs 4.8%).
Both trials presented at ACC.26 and simultaneously published in The New England Journal of Medicine; data support expanded indications.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.